Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis.

Autor: Monroy-Iglesias MJ; Translational Oncology & Urology Research (TOUR), King's College London, London SE1 9RT, UK., Moss C; Translational Oncology & Urology Research (TOUR), King's College London, London SE1 9RT, UK., Beckmann K; Translational Oncology & Urology Research (TOUR), King's College London, London SE1 9RT, UK.; Cancer Research Institute, University of South Australia, Adelaide, SE 5001, Australia., Hammar N; Epidemiology Unit, Institute of Environmental Medicine, Karolinska Institute, 171 77 Stockholm, Sweden., Walldius G; Epidemiology Unit, Institute of Environmental Medicine, Karolinska Institute, 171 77 Stockholm, Sweden., Bosco C; Translational Oncology & Urology Research (TOUR), King's College London, London SE1 9RT, UK., Van Hemelrijck M; Translational Oncology & Urology Research (TOUR), King's College London, London SE1 9RT, UK.; Epidemiology Unit, Institute of Environmental Medicine, Karolinska Institute, 171 77 Stockholm, Sweden., Santaolalla A; Translational Oncology & Urology Research (TOUR), King's College London, London SE1 9RT, UK.; Epidemiology Unit, Institute of Environmental Medicine, Karolinska Institute, 171 77 Stockholm, Sweden.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2021 Nov 04; Vol. 13 (21). Date of Electronic Publication: 2021 Nov 04.
DOI: 10.3390/cancers13215540
Abstrakt: Bilirubin has strong antioxidant properties that have been hypothesized to be preventive against the development of cancer. Thus, we aimed to investigate the association between serum total bilirubin (STB) and risk of overall and site-specific cancers in the large Swedish Apolipoprotein Mortality Risk (AMORIS) cohort. We also performed a systematic review and meta-analysis for specific cancer types (colorectal, breast and lung). We found no association between high levels of STB and risk of overall cancer. Regarding site-specific cancer, there was an inverse association between increased STB and lung cancer (Hazard Ratio (HR) for the 4th quartile (Q4) vs. Q1: 0.50; 95%CI: 0.44-0.59) and gynecological cancer (HR for Q4 vs. Q1: 0.86; 95%CI: 0.76-0.99). A positive association was found with melanoma (HR for Q4 vs. Q1: 1.25; 95%CI: 1.06-1.47) and breast cancer (HR for Q4 vs. Q1: 1.13; 95%CI: 1.01-1.25) risk. The meta-analysis showed an inverse association between high levels of STB and risk of lung cancer (Relative risk (RR): 0.69; 95%CI: 0.55-0.86). No associations were seen for colorectal and breast cancer risk. Further studies are required to establish if bilirubin can be used as a biomarker for risk assessment and/or as a novel therapeutic target.
Databáze: MEDLINE
Externí odkaz: